Anbogen Therapeutics And The University Of Tokyo Enter Collaborative Research Agreement To Evaluate ABT-301 Across Multiple Tumor Types, Targeting Accelerated Human Clinical Indication Expansion
Anbogen Therapeutics and the University of Tokyo have announced a partnership to evaluate ABT-301 across multiple tumor types, aiming to accelerate clinical development.
